Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.39 |
| ▸ | ME2 | P23368 | 6/20 | 0.38 |
| ▸ | ME1 | P48163 | 6/20 | 0.38 |
| ▸ | ME3 | Q16798 | 6/20 | 0.38 |
| ▸ | PIM1 | P11309 | 2/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | IDH1 | O75874 | 3/20 | 0.36 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14923656 | 0.82 | GRIN2D (0.41) | MAP4K1PIM1EEDSUZ12EZH2 | |
| SCHEMBL411695 | 0.81 | AKR1C3 (0.46) | MAP4K1PIM1EEDSUZ12EZH2 | |
| SCHEMBL13424162 | 0.81 | IDH1 (0.38) | MAP4K1PIM1EEDSUZ12EZH2 | |
| SCHEMBL9964663 | 0.81 | DGAT1 (0.40) | PIM1IDH1GRM5 | |
| SCHEMBL17221105 | 0.80 | VHL (0.38) | MAP4K1PIM1EEDSUZ12EZH2 | |
| SCHEMBL17221384 | 0.78 | KCNJ1 (0.43) | MAP4K1PIM1EEDSUZ12EZH2 | |
| SCHEMBL17232492 | 0.77 | HRH3 (0.38) | MAP4K1PIM1EEDSUZ12EZH2 | |
| SCHEMBL14946762 | 0.77 | DGAT1 (0.43) | MAP4K1PIM1IDH1GRM5 | |
| SCHEMBL28941034 | 0.77 | MAPT (0.44) | MAP4K1 | |
| SCHEMBL14910347 | 0.76 | ALDH1A1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1702919-B1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | MSD KK (JP) | 2012-05-30 | — | — | EP | disclosed |
| US-7728025-B2 | 2-heteroaryl-substituted benzimidazole derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | MSD K.K. (JP) | 2008-03-20 | — | — | US | disclosed |
| EP-1702919-A1 | NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070928-A1 | Novel 2-Heteroaryl-Substituted Benzimidazole Derivative | GCK, GCKR, HK1 | MAP4K1 675/4885ME2 61/4885ME1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.